Table 3.

Safety assessment and adverse event follow-up of participant.

	M0	M1	M2	M3
Liver function: alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, globulin	√			√
Renal function: creatinine, blood urea nitrogen, and eGFR calculated by the CKD-EPI equation	√			√
Creatine kinase (CK), creatine kinase myocardial band (CK-MB), lactate dehydrogenase (LDH), alkaline phosphatase (ALP)	√			√
Electrolytes: calcium (Ca), phosphorus(P), potassium(K), magnesium (Mg), sodium (Na), chloride (Cl)	√			√
Closely follow up on the physical health after injection, and receive consultation and feedback at any time within 24 h	√	√	√	√
Did the participant experience any adverse reactions after the injection (whether or not determined to be related to this injection)	√	√	√	√
Digestive adverse reactions: decreased appetite, constipation or diarrhea, abdominal pain, nausea, or vomiting	√	√	√	√
Skin adverse reactions: pruritus, allergic dermatitis, rash, swelling, and pain at the injection site	√	√	√	√
Nervous system adverse reactions: metallic sensation in the mouth, persistent headache, convulsions, and insomnia	√	√	√	√
Urinary adverse reactions: cloudy urine, nocturnal polyuria, and hematuria	√	√	√	√
Skeletal system adverse reactions: bone pain and myalgia	√	√	√	√
Respiratory and circulatory system: shortness of breath, palpitations, hypertension, shock, hypotension, and chest pain	√	√	√	√
Hematologic and endocrine adverse reactions: rapid weight loss or gain, fever, and fear of cold	√	√	√	√
Other adverse reactions: fatigue, asthenia, dry mouth, and fall	√	√	√	√
Record treatment for adverse reactions (only for participants with adverse events)	√	√	√	√

M0, baseline assessment; M1, 1 month from baseline; M2, 2 months from baseline; M3, 3 months from baseline; eGFR, estimated glomerular filtration rate; CKD-EPI, the Chronic Kidney Disease Epidemiology Collaboration equation.